Search

Author/Creator Mirshafiey, Abbas

1. A controlled, randomized phase II clinical trial for efficacy and safety evaluation of mannuronic acid in secondary progressive form of multiple sclerosis. (3rd April 2022)

Authors:
Najafi, Soheil; Moghadam, Nahid Beladi; Saadat, Payam; Noorbakhsh, Seyyedeh Masoomeh; Mohammadi, Anita Vali; Manouchehrinia, Ali; Hosseini, Mostafa; Matsuo, Hidenori; Mirshafiey, Abbas
Journal:
International journal of neuroscience
Issue:
Volume 132:Number 4(2022)
Page Start:
403
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A randomized clinical trial for the assessment of the efficacy and safety of guluronic acid (G2013) in patients with rheumatoid arthritis. (2nd January 2019)

Authors:
Khadem Azarian, Shahin; Akhlaghi, Maassoumeh; Mahmoudi, Mahdi; Mostafaei, Shayan; Jamshidi, Ahmad Reza; Nazeri, Sepideh; Mirshafiey, Abbas
Journal:
Immunopharmacology and immunotoxicology
Issue:
Volume 41:Number 1(2019)
Page Start:
95
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A randomized, controlled, phase II clinical trial of β‐D‐mannuronic acid (M2000) in pre‐surgical breast cancer patients at early stage (T1‐T2). (26th April 2019)

Authors:
Kashefi, Sarvenaz; Omranipour, Ramesh; Mahmoodzadeh, Habibollah; Ahmadi, Hamid; Alikhassi, Afsaneh; Hosseini, Mostafa; Cuzzocrea, Salvatore; Rehm, Bernd H. A.; Matsuo, Hidenori; Mirshafiey, Abbas
Journal:
Clinical and experimental pharmacology and physiology
Issue:
Volume 46:Number 6(2019)
Page Start:
527
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. An in vitro assessment for evaluating the efficiency of β‐d‐mannuronic acid (M2000) in myelodysplastic syndrome. Issue 8 (10th December 2018)

Authors:
Bakhtiari, Tahereh; Ghaderi, Afshin; Safaee Nodehi, Sayyed Reza; Aghazadeh, Zahra; Tofighi Zavareh, Farzaneh; Jafarnezhad‐Ansariha, Fahimeh; Barati, Anis; Mirshafiey, Abbas
Journal:
Journal of cellular physiology
Issue:
Volume 234:Issue 8(2019:Aug.)
Page Start:
12971
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Anti‐angiogenesis effect of β‐D‐mannuronic acid (M2000) as a novel NSAID with immunosuppressive properties under experimental model. (4th February 2018)

Authors:
Rastegari‐Pouyani, Mohsen; Mostafaie, Ali; Mansouri, Kamran; Mortazavi‐Jahromi, Seyed Shahabeddin; Mohammadi‐Motlagh, Hamid‐Reza; Mirshafiey, Abbas
Journal:
Clinical and experimental pharmacology and physiology
Issue:
Volume 45:Number 4(2018)
Page Start:
370
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model. (4th July 2018)

Authors:
Mortazavi-Jahromi, Seyed Shahabeddin; Alizadeh, Shahab; Javanbakht, Mohammad Hassan; Mirshafiey, Abbas
Journal:
Immunopharmacology and immunotoxicology
Issue:
Volume 40:Number 4(2018)
Page Start:
284
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORγt gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis. (2nd January 2018)

Authors:
Mousavi Nasl-khameneh, Ateke; Mirshafiey, Abbas; Naser Moghadasi, Abdorreza; Chahardoli, Reza; Mahmoudi, Maryam; Parastouei, Karim; Yekaninejad, Mir Saeed; Saboor-Yaraghi, Ali Akbar
Journal:
Neurological research
Issue:
Volume 40:Number 1(2018)
Page Start:
11
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗